What is Inbrija?
Inbrija is not to be used in place of any medicine you take daily for Parkinson's disease.
It is not known if Inbrija is safe or effective in children.
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Before taking this medicine
Do not use Inbrija if you have used an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.
To make sure Inbrija is safe for you, tell your doctor if you have:
involuntary muscle movements;
a sleep disorder that causes daytime sleepiness;
mental illness or psychosis; or
an intense urge or compulsive behavior (such as sexual urges, binge eating, gambling, or spending money).
It is not known whether Inbrija inhalation will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.
How should I use Inbrija?
Use Inbrija exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Inbrija is for use only in people who are currently taking carbidopa and levodopa. Do not stop taking your daily Parkinson's medications or change your dosing schedule without your doctor's advice.
For best results, use Inbrija when an "off episode" begins (when your Parkinson's symptoms start to return). Do not use Inbrija more than 5 times per day.
Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you do not understand these instructions.
Inbrija is a powder that comes with a special inhaler device and blister packs containing capsules of the medicine. You will load 2 capsules (one at a time) into the inhaler device each time you use the medicine. Pushing the handle of the device onto the mouthpiece will pierce the capsule and release the medicine into the inhaler.
Do not swallow a Inbrija capsule. It is for use only in the Inbrija inhaler device.
This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using Inbrija.
Do not stop using Inbrija suddenly after long-term regular use, or you could have unpleasant withdrawal symptoms (fever, confusion, muscle stiffness, changes in breathing and heart rate). Ask your doctor how to safely stop using this medicine.
Store at room temperature away from moisture and heat. Keep each capsule in the blister pack until you ready to load the inhaler device. Do not store capsules inside the device.
Throw away the device when your capsules run out. Always use the inhaler device that comes with each new prescription.
Usual Adult Dose for Parkinson's Disease:
84 mg via oral inhalation as needed when OFF period starts to return; may dose up to 5 times a day
Maximum dose per OFF period: 84 mg
Maximum daily dose: 420 mg
-Therapy should be taken when symptoms of an OFF period start to return.
-This drug has shown efficacy only in combination with levodopa/carbidopa therapy.
-Oral inhalation capsules should only be used with the Inbrija(R) inhaler; capsules should not be swallowed whole as the intended effect will not be obtained.
Use: For the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.
What happens if I miss a dose?
Since Inbrija is used when needed, you may not be on a dosing schedule. Skip any missed dose if it's almost time for your next dose. Do not use two doses at one time.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Overdose symptoms may include muscle pain or weakness, fever, dark colored urine, little or no urination, fast heartbeats, or fainting.
What should I avoid while using Inbrija?
Avoid driving or hazardous activity until you know how Inbrija will affect you. Dizziness or drowsiness can cause falls, accidents, or severe injuries.
Inbrija side effects
Get emergency medical help if you have signs of an allergic reaction to Inbrija: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using Inbrija and call your doctor or seek emergency medical attention if you have a wheezing, chest tightness, or trouble breathing after inhaling this medicine.
Call your doctor at once if you have:
extreme drowsiness, falling asleep suddenly (even after feeling alert);
nausea, sweating, and a light-headed feeling (like you might pass out);
uncontrolled muscle movements in your face (chewing, lip smacking, frowning, tongue movement, blinking or eye movement);
confusion, paranoia, hallucinations (seeing or hearing things that are not real);
unusual thoughts or behavior;
trouble sleeping, or increased dreaming;
agitation, aggression; or
increased sexual urges, unusual urges to gamble, or other intense urges.
Some people using this medicine have fallen asleep during normal daytime activities such as working, talking, eating, or driving. This side effect has occurred up to 1 year after the start of treatment with Inbrija. Tell your doctor if you have any problems with daytime drowsiness.
Common Inbrija side effects may include:
sweat, urine, or saliva that appears dark in color.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Inbrija?
Tell your doctor about all your other medicines, especially:
risperidone or other antipsychotic medication;
a multivitamin or mineral supplement that contains iron; or
other medicines to treat Parkinson's disease.
This list is not complete. Other drugs may interact with levodopa, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
The short-acting (immediate-release) formulation of carbidopa/levodopa takes effect within about 20 to 50 minutes. The long-acting (extended-release) formulation starts to work closer to the 50-minute timeframe. Continue reading
The immediate-release (short-acting) form of carbidopa/levodopa is usually taken 3 or 4 times each day, while the extended-release (long-acting) form is typically taken 2 to 4 times each day. Continue reading
Carbidopa/levodopa is unlikely to cause high blood pressure (hypertension). It was reported in less than 1% of patients in clinical trials and is not considered a common adverse reaction related to the drug. Continue reading
Levodopa is a central nervous system agent that helps people with Parkinson’s because it is converted into dopamine in the brain. It helps to alleviate the symptoms of the disease by providing a supply of dopamine, which is lacking in people with Parkinson's.
Levodopa works best to help treat the slowness and stiffness or rigidity associated with Parkinson’s disease, and in some cases may treat the tremor as well. It does not slow or reduce the progression of Parkinson’s disease. Continue reading
The recommended time to take Ongentys (opicapone) is once daily at bedtime and at least one hour after food. Eating is also not recommended for an hour of taking Ongentys.
By taking Ongentys at night or at least one hour apart from levodopa, the amount of levodopa available after a dose is increased, but any interaction between the two drugs during the levodopa absorption phase is avoided. Taking Ongentys at night means that there’s greater flexibility to adjust when levodopa is taken during the day, without the need to consider potential absorption interactions. Continue reading
- How long does it take for Inbrija to work?
- How do you use an Inbrija inhaler?
- What foods should be avoided when taking levodopa?
- What is the difference between carbidopa, levodopa, and Rytary?
More about Inbrija (levodopa)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- En español
Related treatment guides
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Inbrija only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2023 Cerner Multum, Inc. Version: 4.01.